carboplatin + lazertinib + pemetrexed

This is a combination regimen consisting of three drugs—carboplatin, lazertinib, and pemetrexed—used in the treatment of non-small cell lung cancer (NSCLC), particularly in patients with EGFR-sensitizing mutations. - **Carboplatin** is a platinum-based chemotherapy agent that causes DNA crosslinking and inhibits DNA synthesis, leading to apoptosis in rapidly dividing cells. - **Lazertinib** is an oral third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that selectively targets both sensitizing and T790M resistance mutations in EGFR, blocking downstream signaling pathways involved in tumor proliferation and survival. - **Pemetrexed** is an antifolate antineoplastic agent that disrupts folate-dependent metabolic processes essential for cell replication by inhibiting multiple enzymes involved in purine and pyrimidine synthesis. The combination aims to maximize anti-tumor efficacy by targeting both the EGFR pathway (with lazertinib) and providing cytotoxic effects through chemotherapy agents (carboplatin and pemetrexed). This regimen has been investigated as first-line therapy for advanced or metastatic NSCLC with EGFR mutations[2][5].